Curcumin-inspired PARP-1 inhibitor BOD-20 triggers stress-driven death in triple-negative breast cancer cells
A curcumin-derived compound blocks PARP-1 and activates ER stress, killing triple-negative breast cancer cells in a dish while sparing normal breast cells.
Summary
Curcumin has limited stability and absorption, so chemists built a modified version called BOD-20 to block PARP-1, a DNA-repair enzyme that some cancers rely on. In a lab-dish study, BOD-20 blocked PARP-1 at low concentrations and was most potent against MDA-MB-231 triple-negative breast cancer cells. It was much less toxic to normal MCF10A breast cells. The compound pushed cancer cells toward mitochondria-mediated apoptosis and switched on the PERK/eIF2α/ATF-4/CHOP endoplasmic reticulum stress pathway. It also halted cells in the G2/M phase of the cell cycle. All of this was shown in cultured cells and computer simulations only. No animal or human data are reported in the abstract, so BOD-20 is a research tool and early lead, not a treatment or a supplement.
Detailed Summary
Triple-negative breast cancer (TNBC) is an aggressive subtype with few targeted options, and PARP-1 inhibitors are one of the drug classes used against it. Curcumin, the turmeric polyphenol, has long attracted interest as an anticancer molecule but is held back by poor stability and bioavailability. This study asks whether a redesigned, curcumin-inspired molecule can inhibit PARP-1 selectively and engage cell-stress death pathways.
The researchers tested BOD-20, an α,β-unsaturated dienone derivative carrying several bromine and methoxy groups. They measured PARP-1 inhibition, modeled binding with docking and 100-nanosecond molecular dynamics simulations, and assessed cytotoxicity in five human cancer cell lines and in normal MCF10A mammary epithelial cells. Mechanisms were probed with western blotting, immunofluorescence and flow cytometry.
BOD-20 inhibited PARP-1 with an IC50 of 125.5 nM, and simulations suggested stable binding in the NAD+ pocket through hydrogen bonds, halogen bonds and hydrophobic contacts. It was antiproliferative across all five cancer lines, most potent in MDA-MB-231 TNBC cells (IC50 2.00 μM), versus an IC50 above 20 μM in normal MCF10A cells. In MDA-MB-231 cells it raised Bax, lowered Bcl-2, increased PERK, eIF2α, ATF-4 and CHOP, and caused G2/M arrest and apoptosis.
The mechanistic signal is that PARP-1 inhibition by this compound is accompanied by activation of the ER stress arm of the unfolded protein response, which feeds into mitochondrial apoptosis. The authors frame BOD-20 as a chemical tool for studying that crosstalk and for toxicology and drug-safety assessment.
Caveats are substantial. This is cell-line work plus modeling, from the abstract only. The abstract does not report animal efficacy, pharmacokinetics, off-target effects or safety in living organisms. It also does not show that ER stress is required for the killing, and nothing here concerns lifespan or function. Nothing here supports taking curcumin as a cancer treatment.
Key Findings
- Mechanism: BOD-20 inhibited PARP-1 with an IC50 of 125.5 nM, with modeled stable binding in the NAD+ pocket (docking and 100 ns simulations).
- Selectivity in vitro: IC50 was 2.00 μM in MDA-MB-231 TNBC cells versus above 20 μM in normal MCF10A breast cells.
- Pathways: BOD-20 raised Bax, lowered Bcl-2, and increased PERK, eIF2α, ATF-4 and CHOP, consistent with ER stress and mitochondrial apoptosis.
- Cell cycle: flow cytometry showed G2/M arrest and apoptosis in MDA-MB-231 cells; no in vivo, function or lifespan data are reported.
Methodology
Preclinical study combining biochemical PARP-1 inhibition assays, molecular docking, 100 ns molecular dynamics simulations, and in vitro cytotoxicity across five human cancer cell lines plus normal MCF10A cells. Mechanism was assessed by western blotting, immunofluorescence and flow cytometry in MDA-MB-231 cells. Replicate numbers and controls were not available in the abstract.
Study Limitations
This summary is based on the abstract only, so sample sizes, replicates and statistics could not be assessed. Evidence is limited to cultured cells and simulations; there is no animal efficacy, pharmacokinetic or toxicity data, and the abstract does not show that ER stress is causally required for cell death. The normal-cell comparison used a single non-malignant line.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
